BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21518332)

  • 21. Temozolomide: too early for definitive conclusions.
    Brown P; Buckner J
    J Clin Oncol; 2003 Oct; 21(19):3710. PubMed ID: 14512412
    [No Abstract]   [Full Text] [Related]  

  • 22. Temozolomide in malignant gliomas: current use and future targets.
    Villano JL; Seery TE; Bressler LR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma--case report.
    Faraji AH; Engh JA; Horowitz M; Lunsford LD; Park DM
    Clin Neurol Neurosurg; 2013 May; 115(5):632-5. PubMed ID: 22795303
    [No Abstract]   [Full Text] [Related]  

  • 24. Non-Hodgkin's lymphoma in a patient on treatment with temozolomide.
    Otty Z; Sabesan S
    Asia Pac J Clin Oncol; 2012 Dec; 8(4):e53-4. PubMed ID: 22897453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
    Dufour C; Da Costa L; Auger N; Jullien M; Bhangoo R; Grill J
    J Pediatr Hematol Oncol; 2008 Nov; 30(11):857-9. PubMed ID: 18989164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
    Gupta T; Mohanty S; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
    Khasraw M; Bell D; Wheeler H
    J Clin Neurosci; 2009 Jun; 16(6):854-5. PubMed ID: 19303779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma.
    Hartmann P; Herholz K; Salzberger B; Petereit HF
    Ann Hematol; 2004 Apr; 83(4):212-7. PubMed ID: 14648028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
    Alonso-Llamazares A; Vega-Castro A; Beitia-Mazuecos JM; Mateo-Borrega B; Cardenas-Contreras R
    J Investig Allergol Clin Immunol; 2012; 22(6):448-9. PubMed ID: 23101195
    [No Abstract]   [Full Text] [Related]  

  • 30. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
    Harris MT; Rosenthal MA; Ashley DL; Cher L
    J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Radiation and temozolomide therapy].
    Sonoda Y
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():619-22. PubMed ID: 25831834
    [No Abstract]   [Full Text] [Related]  

  • 32. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
    Wick W; Weller M
    J Clin Oncol; 2005 Jun; 23(18):4235-6; author reply 4236. PubMed ID: 15961774
    [No Abstract]   [Full Text] [Related]  

  • 33. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
    Yaman E; Buyukberber S; Benekli M; Oner Y; Coskun U; Akmansu M; Ozturk B; Kaya AO; Uncu D; Yildiz R
    Clin Neurol Neurosurg; 2010 Oct; 112(8):662-7. PubMed ID: 20627551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide for melanoma: new toxicities and new opportunities.
    Gajewski TF
    J Clin Oncol; 2004 Feb; 22(4):580-1. PubMed ID: 14726506
    [No Abstract]   [Full Text] [Related]  

  • 35. Is protracted low-dose temozolomide feasible in glioma patients?
    Tosoni A; Cavallo G; Ermani M; Scopece L; Franceschi E; Ghimenton C; Gardiman M; Pasetto L; Blatt V; Brandes AA
    Neurology; 2006 Feb; 66(3):427-9. PubMed ID: 16476947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
    Treudler R; Georgieva J; Geilen CC; Orfanos CE
    J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
    Fang HH; Nie Q; Kang JB; Li FM; Cai CL
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):707-9. PubMed ID: 22340055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
    Rinne ML; Wen PY
    Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491
    [No Abstract]   [Full Text] [Related]  

  • 39. [Problems of chemotherapy for glioma].
    Hirose Y
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):923-6. PubMed ID: 21751527
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.
    Grant LM; Kleiner DE; Conjeevaram HS; Vuppalanchi R; Lee WM
    Dig Dis Sci; 2013 May; 58(5):1415-21. PubMed ID: 23212393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.